The relevance of CYSLTR1 gene polymorphism to the severity of allergic rhinitis and clinical responsiveness of montelukast in children

Eur Arch Otorhinolaryngol. 2021 Dec;278(12):4847-4853. doi: 10.1007/s00405-021-06771-z. Epub 2021 Apr 10.

Abstract

Purpose: The etiology of allergic rhinitis (AR) is closely correlated with the complex interactions between genetic and environmental factors. This study explored the effect of single-nucleotide polymorphisms (SNPs) of CYSLTR1 gene on the risk of AR and clinical response to montelukast treatment in children.

Methods: A total of 135 children with AR and 100 healthy children were included for subsequent analyses. Genotype and allele distribution of rs321029 SNP of CYSLTR1 gene and inflammatory mediators were detected and compared between AR and healthy children.

Results: Genotype and allele frequency of rs321029 SNP of CYSLTR1 gene showed no difference between children with AR and controls or between AR cases with different severity. The total montelukast effective rate of wide-type genotype TT children was significantly higher than variants genotype CC children.

Conclusion: Polymorphism of rs321029 on CYSLTR1 gene is not related to the susceptibility and severity of AR in children, but it is closely related with the efficacy of montelukast on AR.

Keywords: Allergic rhinitis; CYSLTR1; Gene polymorphism; Montelukast.

MeSH terms

  • Acetates / therapeutic use
  • Anti-Asthmatic Agents / therapeutic use*
  • Child
  • Cyclopropanes
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Polymorphism, Single Nucleotide
  • Quinolines* / therapeutic use
  • Receptors, Leukotriene / genetics*
  • Rhinitis, Allergic* / drug therapy
  • Rhinitis, Allergic* / genetics
  • Sulfides

Substances

  • Acetates
  • Anti-Asthmatic Agents
  • Cyclopropanes
  • Quinolines
  • Receptors, Leukotriene
  • Sulfides
  • leukotriene D4 receptor
  • montelukast